Screener
Xenon Pharmaceuticals XENE Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Accounts payable and accrued liabilities | 3,915 | (2,914) |
| Operating lease liability | (707) | (625) |
| Other liabilities | 88 | — |
| Net cash used in operating activities | (184,287) | (125,885) |
| Investing activities: | ||
| Purchases of property, plant and equipment | (408) | (200) |
| Purchases of marketable securities | (996,034) | (220,055) |
| Proceeds from marketable securities | 257,922 | 337,025 |
Item 1. Financial Statements
FAQ
- What is Xenon Pharmaceuticals's operating cash flow?
- Xenon Pharmaceuticals (XENE) reported operating cash flow of -$95.39M in Q2 2026.
- How has Xenon Pharmaceuticals's operating cash flow changed year-over-year?
- Xenon Pharmaceuticals's operating cash flow decreased by 48.5% year-over-year, from -$64.23M to -$95.39M.
- What is the long-term trend for Xenon Pharmaceuticals's operating cash flow?
- Over 4 years (2021 to 2025), Xenon Pharmaceuticals's operating cash flow has grown at a 41.6% compound annual growth rate (CAGR), from -$69.5M to -$279.12M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Xenon Pharmaceuticals's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude